For research use only. Not for therapeutic Use.
Gboxin is an oxidative phosphorylation (OXPHOS) inhibitor that targets glioblastoma. Gboxin inhibits the activity of F0F1 ATP synthase. Antitumour activity[1].
Gboxin (0-15 μM; 96 hours) specifically inhibit the growth of primary ‘high-throughput GBM sphere’ (HTS) cells but not that of cycling primary low-passage mouse embryonic fibroblasts (MEFs) or astrocytes[1].
| Catalog Number | I019486 |
| CAS Number | 2101315-36-8 |
| Synonyms | [(1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl] 2-(2-ethyl-3-methylbenzimidazol-3-ium-1-yl)acetate;chloride |
| Molecular Formula | C22H33ClN2O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C22H33N2O2.ClH/c1-6-21-23(5)18-9-7-8-10-19(18)24(21)14-22(25)26-20-13-16(4)11-12-17(20)15(2)3;/h7-10,15-17,20H,6,11-14H2,1-5H3;1H/q+1;/p-1/t16-,17+,20-;/m1./s1 |
| InChIKey | UBWVTCCKVGOTBG-VYZBTARASA-M |
| SMILES | CCC1=[N+](C2=CC=CC=C2N1CC(=O)OC3CC(CCC3C(C)C)C)C.[Cl-] |
| Reference | [1]. Shi Y, et al. Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma. Nature. 2019 Mar;567(7748):341-346. |
